Related Experiment Video
Updated: Jul 14, 2026

Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages
Published on: May 24, 2019
Characterisation of the anti-apoptotic function of survivin-DeltaEx3 during TNFalpha-mediated cell death
M-H Malcles1, H-W Wang, A Koumi
1Cancer Research UK Viral Oncology Group, Wolfson Institute for Biomedical Research, University College, London, UK.
Abstract:
Survivin is an oncogenic protein involved in cell division and acts as an anti-apoptotic factor. It is highly expressed in most cancers and is associated with chemotherapy resistance, increased tumour recurrence, and shorter patient survival. This makes anti-survivin therapy an attractive cancer treatment strategy. These functions are mediated by several survivin spliced variants, whose expression may correlate with cancer progression. One of the spliced variants, survivin-DeltaEx3, is known to inhibit apoptosis, through undefined mechanisms. Here, we characterised these mechanisms upon TNFalpha-mediated apoptosis, and showed that survivin-DeltaEx3 acts as an adaptor, allowing the formation of a complex between Bcl-2 and activated caspase-3. The Bcl-2/survivin-DeltaEx3 complex, but not survivin-DeltaEx3 itself, inhibits the activity of caspase-3. Bcl-2 is therefore linked to the postmitochondrial apoptotic machinery by survivin-DeltaEx3. Thus, survivin-DeltaEx3 plays a key role in the inhibition of caspase-3 activity, and in the control of the mitochondrial checkpoint of apoptosis. This study suggests that targeting survivin-DeltaEx3, rather than survivin alone, could be relevant for treating human cancers.
Insights
Survivin-DeltaEx3, a cancer-promoting protein variant, inhibits apoptosis by forming a complex with Bcl-2 and caspase-3. Targeting this specific variant may offer a novel cancer treatment strategy.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Death Research
Background:
- Survivin is an oncogenic protein crucial for cell division and apoptosis inhibition.
- High survivin expression in cancers correlates with poor prognosis and treatment resistance.
- Survivin has spliced variants, including survivin-DeltaEx3, which inhibits apoptosis via unknown mechanisms.
Purpose of the Study:
- To elucidate the mechanisms by which survivin-DeltaEx3 inhibits TNFalpha-mediated apoptosis.
- To investigate the interaction of survivin-DeltaEx3 with apoptotic pathway components.
Main Methods:
- Characterization of survivin-DeltaEx3 function in TNFalpha-mediated apoptosis.
- Analysis of protein complex formation involving survivin-DeltaEx3, Bcl-2, and caspase-3.
Main Results:
- Survivin-DeltaEx3 acts as an adaptor protein, facilitating the formation of a Bcl-2/survivin-DeltaEx3/caspase-3 complex.
- The Bcl-2/survivin-DeltaEx3 complex, not survivin-DeltaEx3 alone, inhibits activated caspase-3 activity.
- Survivin-DeltaEx3 links Bcl-2 to the postmitochondrial apoptotic machinery, controlling the mitochondrial apoptotic checkpoint.
Conclusions:
- Survivin-DeltaEx3 plays a critical role in suppressing caspase-3 activity and regulating apoptosis.
- Targeting survivin-DeltaEx3, rather than survivin broadly, presents a promising strategy for cancer therapy.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Apoptosis
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized by phagocytes.
Cellular Injury V: Apoptosis and Autophagy
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...

